An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Multiple myeloma is a B-cell malignancy characterized by the uncontrolled growth of plasma cells in the bone marrow and the development of osteolytic bone disease. Myeloma cells express the receptor activator of nuclear factor κB ligand (RANKL), induce RANKL expression in the bone marrow, and down-regulate expression of the decoy receptor osteoprotegerin, thereby promoting bone resorption. Targeting this system in myeloma has clear therapeutic potential. However, osteoprotegerin also binds tumor necrosis factor–related apoptosis inducing ligand (TRAIL) and prevents TRAIL-induced apoptosis of myeloma cells. Whether or not osteoprotegerin can bind TRAIL and prevent apoptosis in vivo and the relative importance of osteoprotegerin binding to TRAIL and RANKL are unclear. In the present study, we have investigated the ability of an osteoprotegerin-like peptidomimetic (OP3-4), designed to block the RANKL/RANK interaction, to inhibit osteoclastic bone resorption and TRAIL-induced apoptosis in vitro and myeloma bone disease in vivo. OP3-4 inhibited osteoclast formation (P < 0.01) and bone resorption (P < 0.01) in vitro. However, OP3-4 had no effect on TRAIL-induced apoptosis of RPMI 8226 myeloma cells. Treatment of 5T2MM myeloma–bearing mice with OP3-4 decreased osteoclast number and the proportion of bone surface covered by osteoclasts (P < 0.05). Treatment also prevented the tumor-induced decrease in cancellous bone area and the development of osteolytic lesions (P < 0.05). OP3-4 also reduced tumor burden when compared with the control (P < 0.05). These data suggest that OP3-4 and the selective inhibition of RANKL, but not TRAIL activity, are effective in preventing myeloma bone disease and offer a novel therapeutic approach to treating this aspect of myeloma. [Cancer Res 2007;67(1):202–8]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“RANKL, a tumor necrosis factor (TNF) family member, binds to its receptor RANK on osteoclast precursors to stimulate osteoclastogenesis and bone resorption (5, 6).”
BackgroundRANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746 · cited 1×
“RANKL, a tumor necrosis factor (TNF) family member, binds to its receptor RANK on osteoclast precursors to stimulate osteoclastogenesis and bone resorption (5, 6).”
BackgroundGiuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415
Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383
Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305
RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma.
Roux, S., Meignin, V., Quillard, J., Meduri, G., Guiochon‐Mantel, A., Fermand, J., Milgrom, E., & Mariette, X. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03417.x · Cited by 125
Immunocytochemistry reveals RANKL expression of myeloma cells
Sezer, O., Heider, U., Jakob, C., Zavrski, I., Eucker, J., Possinger, K., Sers, C., & Krenn, V. (2002) · Blood · doi:10.1182/blood-2002-01-0148 · Cited by 110
Human bone marrow myeloma cells express RANKL.
Sezer, O., Heider, U., Jakob, C., Eucker, J., Possinger, K., & Roodman, G. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.353 · Cited by 104
Cheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H., & Murali, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309690200 · Cited by 92 · cited 3×
“We have designed an osteoprotegerin-like peptidomimetic (OP3-4), modeled on the TNF-h-TNF receptor 1 complex, TRAIL-death receptor 5 complex, and Fas-Fas ligand complex, and showed that it functions by inhibiting the RANKL/RANK system (30).”
MethodResultInfluentialSelf-citation
Cited by
Lamoureux, F., Richard, P., Wittrant, Y., Battaglia, S., Pilet, P., Trichet, V., Blanchard, F., Gouin, F., Pitard, B., Heymann, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4130 · Cited by 181
“In the 5T2MM murine model of myeloma, the OPG-like peptidomimetic OP3-4 that selectively inhibits RANKL but not TRAIL prevented the tumor-induced decrease in the cancerous bone area and the development of osteolytic lesions, but also reduced tumor burden when compared with the controls (44).”
BackgroundMethodOsteoprotegerin: Multiple partners for multiple functions
Baud’huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., Redini, F., Heymann, M.-F., & Heymann, D. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.06.001 · Cited by 153
“OP3-4 was able to inhibit osteoclastogenesis of murine blood mononuclear cells but did not inhibit TRAILinduced apoptosis of multiple myeloma cells (Heath et al. 2007).”
BackgroundSafety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence
Perrot, P., Rousseau, J., Bouffaut, A.-L., Rédini, F., Cassagnau, E., Deschaseaux, F., Heymann, M.-F., Heymann, D., Duteille, F., Trichet, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010999 · Cited by 120
Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments
Hu, J., & Hu, W.-X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.020 · Cited by 84
Metadata
- Authors
- Heath, D. J., Vanderkerken, K., Cheng, X., Gallagher, O., Prideaux, M., Murali, R., & Croucher, P. I.
- Venue
- Cancer Research
- Published
- 2007-01-01
- Volume
- 67
- Issue
- 1
- Pages
- 202-208
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2106751714
- Cited by
- 82
- References
- 9
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-1287
- The paper
- Heath, D. J., Vanderkerken, K., Cheng, X., Gallagher, O., Prideaux, M., Murali, R., & Croucher, P. I. (2007). An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-1287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.